导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 11.97% | 743/4758 |
| 近一周 | -0.96% | 1425/5447 |
| 近一月 | -3.78% | 2790/5404 |
| 近一季 | -2.72% | 1472/5214 |
| 近半年 | 2.63% | 1017/4903 |
| 近一年 | 17.83% | 664/4384 |
| 近两年 | 92.11% | 700/2948 |
| 近三年 | 51.50% | 534/2247 |
| 成立以来 | 94.64% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.31% 967/4961 |
19.09% 1323/5312 |
- - |
- - |
| 2025 | 34.40% 1057/4813 |
4.08% 997/3635 |
3.11% 1157/4076 |
22.49% 1646/4524 |
2.24% 1032/4813 |
| 2024 | 5.77% 1812/3463 |
-3.71% 1547/2808 |
-4.83% 1568/3014 |
14.38% 1985/3129 |
0.91% 1151/3463 |
| 2023 | -6.51% 848/2656 |
6.03% 731/2280 |
-5.41% 1444/2385 |
-2.27% 652/2515 |
-4.63% 1120/2655 |
| 2022 | -16.24% 464/2207 |
-12.18% 581/1919 |
6.44% 699/2016 |
-11.67% 556/2113 |
1.45% 1263/2208 |
| 2021 | 16.34% 271/1822 |
-0.32% 350/1255 |
10.59% 448/1330 |
3.61% 400/1466 |
1.86% 772/1822 |
| 2020 | 35.45% 415/1250 |
-1.79% 237/1028 |
20.20% 278/1067 |
10.15% 582/1164 |
4.16% 861/1184 |
| 2019 | 31.50% 465/1092 |
29.49% 271/754 |
-7.66% 569/804 |
1.88% 346/850 |
7.95% 377/918 |
| 2018 | -25.82% 364/834 |
- - |
- - |
- - |
-10.61% 208/691 |
| 2017 | 11.26% 297/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.27% 212/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 创金合信中证500指数增强A VS. 长安沪深300非周期A(740101) |